Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
New England Journal of Medicine · 10.07.2025 · 393 (2) · 151-161
DOI: 10.1056/nejmoa2501796 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 10.07.2025. Verfasst von Komal L Jhaveri und 14 weiteren Autor:innen. Beteiligte Einrichtung: Breast and Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Class I Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 134-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Roche, F. Hoffmann–La Roche.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Breast and Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
- Weill Cornell Medical College, New York.
- Seoul National University Hospital, Seoul National University College of Medicine, Cancer Research Institute, Seoul National University, Seoul, South Korea.
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona.
- German Breast Group, Neu-Isenburg, Frankfurt, Germany.
- Center for Hematology and Oncology Bethanien, Goethe University, Frankfurt, Germany.
Förderung
- NCI NIH HHS
- Roche
- F. Hoffmann–La Roche
Zitieren
APA
Jhaveri, K. L., Im, S. A., Saura, C., Loibl, S., Kalinsky, K., Schmid, P., Loi, S., Thanopoulou, E., Shankar, N., Jin, Y., Stout, T. J., Clark, T. D., Song, C., Juric, D., & Turner, N. C. (2025). Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer. New England Journal of Medicine, 393(2), 151-161. https://doi.org/10.1056/nejmoa2501796
Vancouver
Jhaveri KL, Im SA, Saura C, Loibl S, Kalinsky K, Schmid P, et al. Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer. New England Journal of Medicine. 2025;393(2):151-161. doi:10.1056/nejmoa2501796
BibTeX
@article{Jhaveri2025,
author = {Jhaveri, Komal L and Im, Seock-Ah and Saura, Cristina and Loibl, Sibylle and Kalinsky, Kevin and Schmid, Peter and Loi, Sherene and Thanopoulou, Eirini and Shankar, Noopur and Jin, Yanling and Stout, Thomas J and Clark, Tiffany D and Song, Chunyan and Juric, Dejan and Turner, Nicholas C},
title = {Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {2},
pages = {151--161},
doi = {10.1056/nejmoa2501796}
}
EUVIMED